Rigel Pharmaceuticals Inc (RIGL) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Rigel Pharmaceuticals Inc. (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease mechanisms. Tavalisse (fostamatinib disodium hexahydrate), the companys first US FDA approved product is an oral spleen tyrosine kinase inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia. Rigel is also evaluating Fostamatinib for autoimmune hemolytic anemia and IgA nephropathy in Phase II trials. The company also has partnered clinical programs with Aclaris, BerGenBio, Daiichi, AstraZeneca and Bristol-Myers Squibb. Rigel is headquartered in South San Francisco, California, the US.

Rigel Pharmaceuticals Inc (RIGL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Rigel Enters into R&D Agreement with Bristol-Myers Squibb for TGF Beta Receptor Kinase Inhibitors 11
Licensing Agreements 12
Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 12
AstraZeneca Enters Into Licensing Agreement With Rigel Pharma For R256 13
Equity Offering 14
Rigel Pharma Prices Public Offering of Shares for USD62.4 Million 14
Rigel Pharma Raises USD69.7 Million in Public Offering of Shares 15
Rigel Pharma Raises USD3.4 Million in Public Offering of Shares 17
Rigel Pharma Raises USD46 Million in Public Offering of Shares 18
Rigel Pharma to Raise up to USD30 Million in Private Placement of Shares 20
Rigel Pharma Completes Public Offering Of Shares For US$145 Million 21
Rigel Pharmaceuticals Inc - Key Competitors 23
Rigel Pharmaceuticals Inc - Key Employees 24
Rigel Pharmaceuticals Inc - Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
May 01, 2018: Rigel Reports First Quarter 2018 Financial Results 26
Mar 06, 2018: Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update 28
Nov 07, 2017: Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update 30
Aug 01, 2017: Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update 31
May 02, 2017: Rigel Announces First Quarter 2017 Financial Results and Provides Company Update 32
Mar 07, 2017: Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results 34
Corporate Communications 36
Dec 15, 2017: Rigel Announces Departure of Chief Financial Officer 36
Nov 02, 2017: Rigel Welcomes Gregg Lapointe to Board of Directors 37
Aug 25, 2017: Rigel Welcomes Brian Kotzin, M.D. to Board of Directors 38
Product News 39
04/17/2018: Rigel Announces FDA Approval of TAVALISSE (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients 39
04/12/2018: Rigel Makes Statement Regarding Website Error 40
01/30/2017: Fostamatinib Study Results Continue to Trend Positive 41
Product Approvals 42
Oct 02, 2017: Rigel Provides Update on FDA Review of Fostamatinib for ITP 42
Jun 19, 2017: FDA Accepts Rigels New Drug Application for TAVALISSE (fostamatinib disodium) for the Treatment of Chronic ITP 43
Apr 27, 2017: Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States 44
Apr 17, 2017: Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP 45
Clinical Trials 46
Jun 26, 2018: Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases 46
Apr 30, 2018: TAVALISSE (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo 47
Apr 03, 2018: Rigel Announces Topline Data From Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy 48
Mar 01, 2018: Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America 49
Jan 04, 2018: Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference 50
Dec 08, 2017: Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting 52
Oct 03, 2017: Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia Phase 2 Study 53
Jun 22, 2017: Rigel Announces Oral Presentation of TAVALISSE Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List Of Tables

List of Tables
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rigel Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Rigel Enters into R&D Agreement with Bristol-Myers Squibb for TGF Beta Receptor Kinase Inhibitors 11
Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 12
AstraZeneca Enters Into Licensing Agreement With Rigel Pharma For R256 13
Rigel Pharma Prices Public Offering of Shares for USD62.4 Million 14
Rigel Pharma Raises USD69.7 Million in Public Offering of Shares 15
Rigel Pharma Raises USD3.4 Million in Public Offering of Shares 17
Rigel Pharma Raises USD46 Million in Public Offering of Shares 18
Rigel Pharma to Raise up to USD30 Million in Private Placement of Shares 20
Rigel Pharma Completes Public Offering Of Shares For US$145 Million 21
Rigel Pharmaceuticals Inc, Key Competitors 23
Rigel Pharmaceuticals Inc, Key Employees 24

List Of Figures

List of Figures
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Rigel Pharmaceuticals Inc (RIGL) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Rigel Pharmaceuticals Inc. (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus

USD 250 View Report

Rigel Pharmaceuticals, Inc. - Mergers and Acquisitions (M&A), Partnerships and Alliances and Investment Report

Rigel Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Rigel Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,

USD 350 View Report

Pivot Pharmaceuticals Inc (PVOTF) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Pivot Pharmaceuticals Inc (Pivot Pharmaceuticals), formerly Neurokine Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of cannabinoid based neutraceutical and pharmaceutical products. The companys major

USD 250 View Report

Fog Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Fog Pharmaceuticals Inc (Fog Pharmaceuticals) is a clinical-stage biotechnology company that discovers and develops next-generation peptide inhibitors that target traditionally undruggable intracellular protein-protein interactions. The company develops cell-penetrating miniproteins (CPMPs),

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available